FDA approves Moderna's mRNA seasonal flu vaccine
Summary
The U.S. Food and Drug Administration (FDA) approved Moderna’s new seasonal flu vaccine, called mFLUSIVA, which uses mRNA technology. The vaccine is for adults aged 50 and older and is expected to be available for the 2026-2027 flu season.Key Facts
- The FDA approved Moderna’s mRNA flu vaccine for people 50 and older.
- The vaccine is named mFLUSIVA and will be used for the 2026-2027 respiratory illness season.
- In trials, people aged 50-64 who got the mRNA vaccine had 27% fewer confirmed flu cases than those with the standard vaccine.
- Side effects were mostly mild and lasted two days or less, though more common than with the standard vaccine.
- People 65 and older currently use a high-dose flu vaccine; Moderna will study how mFLUSIVA compares before expanding approval for this group.
- The FDA initially declined to review the vaccine but agreed after Moderna committed to more studies.
- mRNA vaccines can be made faster than traditional flu vaccines, which may help better match current virus strains.
- The flu vaccine is recommended for everyone over 6 months old and helps prevent severe illness, hospitalization, and death.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
